Abstrait

Comparison of Ticagrelor alone and Ticagrelor with aspirin in post percutaneous intervention patients with respect to Cardiovascular morbidity and bleeding complications- A meta-analysis of Randomized controlled trials

Dr Harini Lakshman

The cornerstone therapeutic strategy for post PCI patients has been P2Y12 therapy with Ticagrelor. Ticagrelor while constituting an essential part of post PCI management significantly reducing the cardiovascular mortality has been debated whether to be used with aspirin in patients with high risk of bleeding. While aspirin has remained the gold standard for both primary and secondary prevention of CAD, stopping aspirin safely post PCI while Ticagrelor alone is used is being debated. This meta-analysis will assess the difference between using Ticagrelor alone and stopping aspirin Vs using both aspirin and Ticagrelor post PCI